Article

FDA expands indication for bromfenac use

Irvine, CA—ISTA Pharmaceuticals Inc. announced that the FDA has approved its supplemental new drug application (sNDA) for bromfenac ophthalmic solution 0.09% (Xibrom). The indication expands bromfenac's indication to include the treatment of pain following cataract surgery.

Irvine, CA-ISTA Pharmaceuticals Inc. announced that the FDA has approved its supplemental new drug application (sNDA) for bromfenac ophthalmic solution 0.09% (Xibrom). The indication expands bromfenac's indication to include the treatment of pain following cataract surgery.

Bromfenac, a topical, twice-daily, non-steroidal anti-inflammatory solution, was originally approved by the FDA in March 2005 for the treatment of ocular inflammation following cataract surgery.

ISTA launched the drug in the United States during the second quarter of 2005.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.